Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Briacell Therapeutics Corp BCTXW


Primary Symbol: T.BCT Alternate Symbol(s):  BCTX

Healthcare Biotechnology
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted... see more

Recent & Breaking News (TSX:BCT)

BriaCell (TSXV:BCT) is advancing the fight with its immunotherapy

Brieanna McCutcheon  October 5, 2021

October is Breast Cancer Awareness Month - BriaCell is Advancing the Fight with its Immunotherapy

GlobeNewswire October 5, 2021

BriaCell Therapeutics CEO Emphasizes Recent Key Developments in Audio Interview with SmallCapVoice.com

GlobeNewswire September 23, 2021

BriaCell Announces TSXV Acceptance of Normal Course Issuer Bid

GlobeNewswire September 22, 2021

BriaCell to Present at the Benzinga Healthcare Small Cap Conference September 29-30

GlobeNewswire September 16, 2021

BriaCell (TSXV:BCT) announces securities buyback program

Brieanna McCutcheon  September 9, 2021

BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants

GlobeNewswire September 9, 2021

Marc Lustig joins BriaCell Therapeutics’ (TSXV:BCT) Board of Directors

John Ballem  September 1, 2021

BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors

GlobeNewswire September 1, 2021

BriaCell to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

GlobeNewswire August 23, 2021

BriaCell (TSXV:BCT) and ImaginAb to evaluate advanced breast cancer with immunotherapy imaging technology

Jocelyn Aspa August 19, 2021

BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer

GlobeNewswire August 19, 2021

BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

GlobeNewswire July 14, 2021

BriaCell to Present at Three Upcoming Investor Conferences

GlobeNewswire July 12, 2021

BriaCell (TSXV:BCT) expands breast cancer technology

Trevor Abes  June 16, 2021

BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers

GlobeNewswire June 16, 2021

BriaCell Therapeutics (TSXV:BCT) announces proceeds of US$12.88 million from warrant exercises

Brieanna McCutcheon  June 10, 2021

BriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises

GlobeNewswire June 10, 2021

BriaCell to Host Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET

GlobeNewswire June 9, 2021

BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement

GlobeNewswire June 7, 2021